Alzheimer's Disease Trial, Recruiting NCT05997030 Sponsor: Ali Rezai Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT05997030
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are a male or non-pregnant female between the ages of 45 and 85
  • You are willing and able to agree to take part in the study after being told what it involves
  • You have been diagnosed with mild memory or thinking problems that are believed to be caused by early Alzheimer's disease
  • If you are already taking certain memory medications (such as donepezil, rivastigmine, galantamine, or memantine), you have been on the same dose for at least 45 days
  • You are able to describe what you feel during the brain treatment procedure used in this study

Who may not be able to join:

  • You cannot have an MRI scan, for example because you have a pacemaker, metal implants, aneurysm clips, cochlear implants, shrapnel, permanent makeup, or small metal fragments in your eyes — or if you feel very uncomfortable in small, enclosed spaces
  • More than 30% of the area of your skull along the treatment path is affected by scars, skin conditions (such as eczema), thinning of the scalp, or you have any implanted devices in your skull or brain
  • You have a history of seizures or a seizure disorder
  • You have a serious ongoing lung condition, such as severe emphysema or pulmonary vasculitis, that significantly affects your lungs (confirm with trial site)
  • You do not speak English
  • You are pregnant or planning to become pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ali Rezai, MD, WVU Rockefeller Neuroscience Institute

Phone: 3042936276

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Ali Rezai
Registry
ClinicalTrials.gov
Start date
12 October 2023
Est. completion
30 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Occurrence of Treatment Emergent Adverse Events; Cognitive Change

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov